is it normal to get sulphur burps at week 87
is it normal to get sulphur burps at week 87. Full detail below, and I have tried to keep the editorialising out of it.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
Disagree.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
Sent a vial to Medutest out of curiosity. Result was 99.5% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
Kept a log specifically because there is so little published. It is one person and it is not data.
heart rate is the thing people report watching
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
dose escalation in the trials was slow for a reason
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.